Confronto

Pasireotid vs. Semax

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

396091-73-9

80714-61-0

Peso molecolare

1047.21 g/mol

813.92 g/mol

Emivita

nessun dato

0.3 h

Sequenza

nessun dato

Met-Glu-His-Phe-Pro-Gly-Pro

Meccanismo d'azione

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Semax

Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studio sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Pasireotid	Semax
Germania	Su prescrizione	Non approvato
RU	—	Su prescrizione
Stati Uniti	Su prescrizione	Non approvato

Voci complete

Frequently asked questions

What is the difference between Pasireotid and Semax?: Pasireotid is classified as "Ricerca (altro)", while Semax is classified as "Ricerca (altro)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pasireotid or Semax?: The highest available evidence level is "RCT sull'uomo" for Pasireotid and "Studio sull'uomo" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pasireotid and Semax in Germany and the United States?: Germania: Pasireotid — Su prescrizione, Semax — Non approvato. Stati Uniti: Pasireotid — Su prescrizione, Semax — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Pasireotid

Semax

Germania

Su prescrizione

Non approvato

—

Su prescrizione

Stati Uniti

Su prescrizione

Non approvato

Frequently asked questions

What is the difference between Pasireotid and Semax?

Pasireotid is classified as "Ricerca (altro)", while Semax is classified as "Ricerca (altro)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pasireotid or Semax?

The highest available evidence level is "RCT sull'uomo" for Pasireotid and "Studio sull'uomo" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pasireotid and Semax in Germany and the United States?

Germania: Pasireotid — Su prescrizione, Semax — Non approvato. Stati Uniti: Pasireotid — Su prescrizione, Semax — Non approvato. These are factual summaries with source and review date on the individual pages.